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at birth and at day 2–3 (Rs 0.902 and 0.897, respectively, p  ! 
0.001), whereas CT-proET-1 was related to NT-proBNP and 
MR-proANP at birth (Rs 0.478 and 0.460, respectively, p  ! 
0.001) but not at day 2–3. Birth weight was negatively related 
to all 3 pro-peptides at birth (p  ! 0.01); however, preeclamp-
sia and compromised placental perfusion were associated 
with elevated NT-proBNP and MR-proANP concentrations at 
birth. At day 2–3, MR-proANP and NT-proBNP correlated sig-
nificantly with the ductal diameter (Rs 0.416 and 0.415, re-
spectively, both p = 0.011), whereas CT-proET-1 correlated 
with the left atrium/aorta ratio (Rs 0.506, p = 0.027). CT-pro-
ET-1 was elevated in infants with treated compared to un-
treated PDA [median (5–95% range) 388 (272–723) vs. 303 
(152–422) pmol/l, p = 0.011], but not NT-proBNP or MR-pro-
ANP.  Conclusion: CT-proET-1 is a promising predictor in de-
termining the need for PDA intervention. 
 Copyright © 2011 S. Karger AG, Basel 
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 Abstract 
 Background: In very preterm infants, clinical decision-mak-
ing, such as closing a patent ductus arteriosus (PDA), may be 
aided by measuring circulating natriuretic and endothelial 
pro-peptides.  Objectives: To investigate the association be-
tween perinatal characteristics, PDA echocardiography and 
plasma concentrations of stable pro-peptides of B-type na-
triuretic peptide (NT-proBNP), atrial natriuretic peptide (MR-
proANP) and endothelin-1 (CT-proET-1).  Methods: A pro-
spective, cross-sectional, single-center study was performed 
in 66 infants who were less than 32 weeks of gestational age. 
Pro-peptide concentrations were determined at birth and at 
day 2–3 of life.  Results: Plasma concentrations of all 3 pro-
peptides increased on average 2- to 5-fold from birth to day 
2–3 of life. NT-proBNP and MR-proANP were closely related 
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 Introduction 
 Patency of the ductus arteriosus (DA) is common in 
preterm infants. Aortopulmonary shunting through the 
patent ductus arteriosus (PDA) augments pulmonary 
blood flow followed by an increase in myocardial load 
and a decrease in systemic blood pressure  [1–3] . The as-
sociation of these hemodynamic alterations with short- 
and long-term morbidities remains a matter of contro-
versy. While echocardiography is the standard procedure 
to detect PDA, it is not always available in all NICUs. 
Moreover, a decision to treat a PDA is complex and may 
be aided by other diagnostic measures, such as chest X-
ray  [4] and circulating plasma biomarkers  [1] . The inabil-
ity of echocardiography to accurately differentiate the 
pathological DA from the innocent DA  [5] supports the 
use of putative biomarkers that integrate hemodynamic 
consequences over time  [1] . Hemodynamic consequences 
of PDA, such as ductal steal from vital organs compro-
mising the cerebral and/or enteric circulations, are more 
important than the stretch on the left atrium/aorta ratio 
(LA/Ao ratio)  [6] . Nonselective treatment of all very pre-
term infants with inhibitors of prostaglandin synthesis is 
not justified due to the side effects, costs and lack of long-
term benefit  [1, 7] . 
 The natriuretic peptides B-type natriuretic peptide 
(BNP) and atrial natriuretic peptide (ANP) are released 
from distended and stressed myocardium in response to 
volume and pressure load. Several studies have demon-
strated increased concentrations of BNP  [8] and its stable 
by-product, N-Terminal-proBNP (NT-proBNP)  [9] , in in-
fants with PDA. Another study has also found increased 
concentrations of the stable by-product of ANP (pro-
ANP) in preterm infants with PDA  [10] . So far, a direct 
comparison of proANP and NT-proBNP has never been 
performed. 
 The release of natriuretic peptides by the distended 
myocardium is an adaptive mechanism that occurs in re-
sponse to a hemodynamically significant PDA to reduce 
volume load. All endothelial cells have the capability to 
synthesize endothelin-1 (ET-1) and release stored ET-1 in 
response to various stressors  [11] . This endothelial vaso-
constrictor may be released from pulmonary vessels in 
response to increased pulmonary blood flow secondary 
to the PDA-mediated left-to-right shunting  [1] . Urinary 
excretion of ET-1, the main endothelial vasoconstrictor, 
has been found to diminish after PDA closure  [12, 13] . 
Circulating ET-1 concentrations can be reliably assessed 
by measuring the stable by-product C-terminal proET-1 
(CT-proET-1)  [14] . Reference values have been established 
in term healthy newborn infants  [15] , but the impact of 
prematurity has not yet been investigated. 
 In this cross-sectional prospective study, we measured 
MR-proANP, NT-proBNP and CT-proET-1 in plasma 
samples of 66 very preterm infants obtained from the 
umbilical cord and repeat samples obtained at 2–3 days 
of life. The findings were related to indices of prematu-
rity and ductal patency. 
 Materials and Methods 
 This blinded, prospective, cross-sectional study included 66 
very preterm infants born at the University Hospital of Zurich 
between February and December 2010. The study participants 
were enrolled after obtaining informed written consent from the 
parents. The institutional review board in Zurich approved this 
study. Infants were eligible if born before 32 weeks of gestational 
age. Gestational age was determined by a combination of the first 
day of the mother’s last menstrual period and an early ultrasound 
scan in the first trimester. Within the study period of 11 months, 
122 infants were born at the University Hospital of Zurich before 
32 weeks of gestational age. Fifteen of the infants died within the 
first hours of life before admission to the NICU due to extreme 
prematurity (23 and 24 weeks of gestational age, n = 9), severe hy-
drops (n = 2) and major congenital abnormalities (n = 4). Of the 
103 infants admitted to the NICU, 2 were excluded because of ma-
jor congenital abnormalities, including structural heart disease. 
Clinical data were recorded as described previously  [16] . None of 
the infants within the study group had a ventricular septum de-
fect, atrial septum defect or developed cystic periventricular leu-
komalacia. All infants who were endotracheally intubated and 
ventilated had exogenous surfactant administration. Placentas 
were histologically examined for signs of chorioamnionitis and 
altered placental perfusion capacity. 
 Venous blood samples were drawn from the umbilical cord at 
the time of delivery and at 2–3 days of life, collected in EDTA 
tubes, and handled as described previously  [17] . Blood sampling 
on day 2–3 was performed in parallel with echocardiography 
(within 0–4 h). Due to limitations in blood volume, the measure-
ments were performed in the following order: NT-proBNP, MR-
proANP and CT-proET-1. Pro-peptides were each measured in a 
single batch with BRAHMS KRYPTOR automated immunofluo-
rescent assays (BRAHMS Biomarkers, Thermo Fisher Scientific, 
Hennigsdorf, Germany). Both fully automated assays are based 
on the sandwich immunoassays described in detail elsewhere (for 
MR-proANP  [18] and CT-proET1  [14] ), and have comparable pre-
cision and lower detection limits. NT-proBNP was analyzed using 
the Roche assay  [19] . 
 Echocardiographic measurements were performed in parallel 
with blood collections at day 2–3 of life by a single sonographer 
(R.A.) using the Siemens Acuson Sequoia Ultrasound machine 
and a 10v4 cardiology multifrequency probe. Two-dimensional, 
M-mode, pulse and color flow Doppler imaging were performed. 
The indication for ductus intervention was based on the presence 
of the following previously established criteria  [20] : presence of 
PDA with left-to-right shunting, narrowest ductal diameter  6 1.5 
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mm and LA/Ao ratio  6 1.5, and diastolic retrograde flow in the 
postductal descending aorta. Treatment of PDA using indometh-
acin (0.6 mg/kg in 3 or 6 doses at intervals of 12 or 24 h, respec-
tively, depending on clinical considerations) commenced when 
indicated immediately after echocardiographic measurement. 
Surgical closure was performed when PDA remained despite 
three courses of indomethacin and when weaning from respira-
tory support failed (n = 3). Prophylactic indomethacin was not 
used during the study period.
 Statistical analyses were made using PASW 18.0 (SPSS Inc., 
Chicago, Ill., USA) in a strictly nonparametric fashion. Continu-
ous variables were given as a median (5–95% range). Additionally, 
Spearman’s rank order correlation coefficients were calculated, 
and either a Mann-Whitney U test, Kruskal-Wallis or Fisher’s ex-
act test was employed as appropriate. p  ! 0.05 was considered sig-
nificant.
 Results 
 Patients 
 Patient characteristics are given in  table 1 . When com-
pared to the infants who did not undergo PDA treatment, 
the infants who underwent PDA treatment had a lower 
gestational age, lower birth weight and more respiratory 
support. 
 Concentrations of Circulating Pro-Peptides at Birth 
and Day 2–3 of Life 
 Plasma concentrations of all 3 pro-peptides [median 
(5–95% range)] at birth and at day 2–3 in the total study 
population of 66 very preterm infants are given in  ta-
Table 1.  Patient characteristics
P DA study group (n = 66) p
intervention (n  = 25) control (n = 41)
Maternal characteristics
Signs of infection at delivery 5 (20) 13 (32) >0.1
Preeclampsia 12 (48) 12 (29) >0.1
Vaginal/abdominal delivery 1/24 (4/96) 6/35 (15/85) >0.1
Fetal characteristics
Small for gestational age, <5th percentile 6 (24) 3 (7) 0.057
Suspect fetal heart rate just prior to delivery 9 (36) 12 (29) >0.1
Antenatal steroids, complete 22 (88) 5 (88) >0.1
Placenta
Compromised placental perfusion 14 (56) 16 (39) >0.1
Chorioamnionitis 3 (12) 12 (29) 0.097
Neonatal characteristics
Gestational age, week 28 (24.7–31.6) 30.7 (26.2–31.9) <0.001
Birth weight, g 960 (573–1,797) 1,400 (806–2,011) <0.001
Arterial cord blood pH 7.32 (7.17–7.43) 7.32 (7.07–7.40) >0.1
Apgar score at 5 min 7 (2–9) 7 (2–9) >0.1
Apgar score at 10 min 8 (3–10) 9 (3–10) >0.1
Male gender 12 (48) 24 (58) >0.1
Postnatal course until day 3 of life
Positive pressure ventilation 14 (56) 12 (29) 0.032
Nasal CPAP 24 (96) 23 (56) <0.01
Intraventricular hemorrhage 3 (12) 4 (10) >0.1
Sepsis with positive blood culture 3 (12) 1 (2) >0.1
Postnatal course until discharge 3 (12) 1 (2) >0.1
Bronchopulmonary dysplasia 2 (8) 1 (2) >0.1
Retinopathy of prematurity (>°I) 2 (8) 0 (0) 0.066
Necrotizing enterocolitis (>°IIa) 0 (0) 1 (2) >0.1
Death 6 (24) 5 (12) >0.1
Echocardiographic assessment 
LA/Ao ratio 1.4 (1.1–2.2) 1.2 (0.7–2.1) 0.013
Narrowest ductal diameter 1.8 (1.4–2.8) 0.0 (0.0–2.8) <0.001
Dat a are given as n (%) or median (5–95% range).
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ble 2 . Changes from birth to day 2–3 are shown in  figure 
1 (only infants with paired samples). Subdividing these 
data as given in  table 2 according to PDA stratification 
showed that the increase of MR-proANP, NT-proBNP 
and CT-proET-1 from birth to day 2–3 was significant 
(p  ! 0.001) for each of the pro-peptides in the interven-
tion (PDA treatment) and in the control group (no PDA 
treatment).
 Relationship between Circulating Pro-Peptides 
 At birth, we noted a close correlation between MR-
proANP and NT-proBNP concentrations (Rs 0.902, p  ! 
0.001, n = 51;  fig.  2 a) within the umbilical cord blood 
samples. A moderate correlation between CT-proET-1 
and MR-proANP (Rs 0.460, p  ! 0.001, n = 52) as well as 
CT-proET-1 and NT-proBNP (Rs 0.478, p  ! 0.001, n = 50) 
was also noted within the umbilical cord samples. With-
in the samples from day 2–3 of life, there was again a close 
correlation between MR-proANP and NT-proBNP (Rs 
0.897, p  ! 0.001, n = 39;  fig. 2 b), but no correlation be-
tween CT-proET-1 and MR-proANP or between CT-pro-
ET-1 and NT-proBNP. No correlations were found be-
tween umbilical cord plasma and day 2–3 concentrations 
of MR-proANP, NT-proBNP and CT-proET-1. 
 Influence of Infants’ Birth Parameters on Pro-Peptide 
Concentrations 
 While birth weight correlated negatively with umbili-
cal cord blood concentrations of MR-proANP (Rs –0.564, 
p  ! 0.001, n = 54), NT-proBNP (Rs –0.492, p  ! 0.001, n = 
51) and CT-proET-1 (Rs –0.345, p = 0.012, n = 52), there 
was only a weak correlation between gestational age and 
MR-proANP concentrations at birth (Rs –0.377, p = 
0.005, n = 54). In addition, MR-proANP, NT-proBNP and 
CT-proET-1 concentrations at birth were higher in in-
fants who were small for their gestational age (Rs –0.398, 
p = 0.003, n = 54; Rs –0.424, p = 0.002, n = 51; Rs –0.420, 
p = 0.002, n = 52, respectively). Day 2–3 concentrations 
of MR-proANP, NT-proBNP and CT-proET-1 were not 
correlated with birth weight or with gestational age. Gen-
der was not associated with any differences in pro-pep-
tide concentrations at birth or day 2–3.
 Weak negative correlations were noted between um-
bilical cord blood pH and umbilical cord blood concen-
trations of MR-proANP and NT-proBNP (Rs –0.337, p = 
0.016, n = 51, and Rs –0.336, p = 0.019, n = 48, respec-
tively). Correlations were also noted between the 5-min 
Apgar scores and MR-proANP and NT-proBNP (Rs 
–0.409, p = 0.002, n = 54, and Rs –0.331, p = 0.018, n = 51, 
respectively). 
 Influence of Parameters before Delivery on Circulating 
Pro-Peptide Concentrations 
 Among the various maternal factors recorded in the 
present study (infection immediately prior to delivery, 
preeclampsia, suspect fetal heart rate tracings and ad-
ministration of antenatal steroids), only preeclampsia 
was associated with higher concentrations of MR-pro-
ANP and NT-proBNP [MR-proANP: median 799 (5–
95% range: 373–2,414) vs. 503 (263–1,711], p = 0.003; NT-
proBNP: 4,403 (1,103–1,4946) vs. 1,760 (568–15,547), p = 
0.011].
Table 2.  Plasma concentrations of pro-peptides at birth and at day 2–3 according PDA stratification
Birth D ay 2–3
control intervention co ntrol intervention
NT-proBNP, mg/ml n = 31 n = 20 n = 21 n = 19
Median 1,908 3,878 8,714 12,030
5–95% range 558–16,858 790–14,708 1,210–35,000 3,198–35,000
p                          0.095                          >0.1
MR-proANP, pmol/l n = 33 n = 20 n = 21 n = 19
Median 535 829 1,201 1,415
5–95% range 265–1,360 339–2,494 357–4,132 623–2,854
p                          0.016                          >0.1
CT-proET-1, pmol/l n = 32 n = 20 n = 9 n = 11
Median 160 176 303 388
5–95% range 82–308 70–326 152–422 272–727
p                          >0.1                          0.011
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 Placenta Histology and Pro-Peptide Concentrations 
 While chorioamnionitis did not influence pro-peptide 
concentrations, supporting the above-mentioned finding 
that there was no association between maternal infection 
and pro-peptide concentrations, there was a significant 
effect of altered placental perfusion capacity. Infants suf-
fering from compromised placental perfusion had elevat-
ed concentrations of MR-proANP, NT-proBNP and CT-
proET-1 in umbilical cord blood compared to the controls 
[MR-pro-ANP: 860 (304–1,340] vs. 505 (262–2,031), p = 
0.013; NT-proBNP: 4,756 (639–15,062) vs. 1,908 (595–
15,546), p = 0.042; CT-proET-1: 192 (90–290) vs. 149 (67–
308), p = 0.01]. 
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 Fig. 3. Plasma concentrations of pro-peptides at day 2–3 of life according to PDA study groups and echocardio-
graphic indices. Pro-peptide plasma concentrations of NT-proBNP, MR-proANP and CT-proET-1 are given 
with respect to PDA treatment groups ( a–c ), ductal diameter ( d–f ) and LA/Ao ratio ( g–i ), as indicated. Concen-
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 Letzner et al. Neonatology 2012;101:116–124 122
 Relation of Postnatal Factors and Pro-Peptide 
Concentrations 
 Infants receiving ventilator support in the first days of 
life (recorded until blood samples at day 2–3 were drawn) 
had significantly higher concentrations of MR-proANP 
and NT-proBNP in umbilical cord blood compared to the 
infants without ventilatory support [MR-proANP: 869 
(370–1,755) vs. 507 (263–1,633), p  ! 0.001, n = 54; NT-
proBNP 5,691 (763–16,308) vs. 1,711 (548–16,084), p = 
0.003, n = 51]. At day 2–3, only CT-proET-1 levels were 
higher in infants receiving ventilator support in the first 
days of life [428 (265–712) vs. 303 (152–382), p = 0.002,
n = 20].
 The infant variables that showed no relation to the 
concentrations of pro-peptides at birth or at day 2–3 were 
as follows: intraventricular hemorrhage, sepsis, broncho-
pulmonary dysplasia, retinopathy of prematurity, necro-
tizing enterocolitis and death.
 Pro-Peptide Concentrations and PDA  
 Infants subjected to PDA treatment (see Materials and 
Methods for criteria) had significantly higher CT-pro-
ET-1 concentrations in day 2–3 blood samples. MR-pro-
ANP and NT-proBNP concentrations were also elevated, 
but not in a statistically significant fashion ( fig. 3 ). MR-
proANP and NT-proBNP concentrations at day 2–3 were 
significantly higher in infants with the ductal diameter 
 6 1.5 mm ( fig.  3 ). In addition, MR-proANP and NT-
proBNP concentrations at day 2–3 correlated significant-
ly with ductal diameter (Rs 0.416 and 0.415, both p = 
0.011, respectively), whereas CT-proET-1 concentrations 
showed no significance regarding difference and correla-
tion. In contrast, CT-proET-1 concentrations at day 2–3 
were significantly higher in infants with LA/Ao ratios 
 6 1.5 ( fig. 3 ), whereas MR-proANP and NT-proBNP only 
showed a trend towards higher concentrations. In addi-
tion, CT-proET-1 and NT-proBNP concentrations at day 
2–3 correlated significantly with the LA/Ao ratio (Rs 
0.506, p = 0.027, and Rs 0.335, p = 0.043, respectively), 
whereas the association between the LA/Ao ratio and 
MR-proANP concentrations failed to reach statistical 
significance (Rs 0.319, p = 0.055). 
 Discussion 
 The definition of a hemodynamically significant PDA 
and the use of medical and surgical procedures is an on-
going debate in neonatology  [21] . Echocardiography is 
the most important testing method, but additional infor-
mation is warranted to guide clinical decision-making. 
Plasma biomarkers may assist this process. We present 
data on the plasma concentrations of MR-proANP, NT-
proBNP and CT-proET-1 at birth and after 2–3 days of 
postnatal adaptation in preterm infants born more than 
8 weeks before the expected date of delivery. 
 The 3 pro-peptides increased from birth to day 2–3 of 
life alongside the infant transition from fetal to postnatal 
circulation ( fig 1 ). Subdividing these data according to 
PDA stratification showed that this increase with postna-
tal transition occurred independently of PDA evolution 
( table 2 ). This supports the previous findings of natriuret-
ic peptides or the respective pro-peptides in infants born 
at term  [22, 23] . With respect to every aspect examined 
in this study, MR-proANP and NT-proBNP displayed a 
close correlation at birth as well as at day 2–3 ( fig 2 ), in-
cluding echocardiographical parameters ( fig 3 ). Our 
study adds ET-1 to the list of peptides with a physiological 
role in the perinatal circulatory adaptation that occurs in 
the fetal-to-neonatal transition period.
 CT-proET-1 concentrations in very preterm infants at 
birth (median 165, range 65–328 pmol/l) and at day 2–3 
of life (322, 152–727 pmol/l) were significantly elevated 
compared to published umbilical cord blood reference 
values for healthy infants born at term (72, 39–115 
pmol/l)  [15] and venous blood samples from healthy 
adults (44, 11–77 pmol/l)  [14] . The high circulating CT-
proET-1 concentrations measured in very preterm in-
fants on day 2–3 of life have been described previously 
only in critically ill adults suffering from severe sepsis or 
heart failure  [14, 24, 25] . We failed to find any association 
between signs of infection (maternal or placental) and 
MR-proANP, NT-proBNP or CT-proET-1 concentra-
tions in umbilical cord blood or in blood samples drawn 
at day 2–3 of life. 
 Although the number of preterm infants in this study 
was small, our data hint to a possible role for CT-proET-1 
in estimating the hemodynamic significance of a PDA. 
While concentrations at day 2–3 of both natriuretic pro-
peptides correlated with ductal diameter, CT-proET-1 
concentrations correlated with the LA:Ao ratio. Addi-
tionally, CT-proET-1 was significantly elevated in infants 
who were subsequently chosen to undergo attempts 
at PDA closure. The limited number of patients may 
explain the lack of power that MR-proANP and NT-
proBNP have to predict or indicate hemodynamic sig-
nificance of PDA ( fig. 3 a, b). The only published data on 
ET-1 concentrations in the urine of preterm infants 
showed a decrease with the pharmacological closure of 
PDA  [12, 13] . 
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